What is the initial management of hematuria?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Initial Management of Hematuria

Begin by classifying hematuria as gross (visible) or microscopic, as this determines malignancy risk and urgency—gross hematuria carries a 30-40% malignancy risk requiring urgent urologic evaluation, while microscopic hematuria has only a 2.6-4% risk and allows for more systematic risk stratification. 1

Immediate Classification and Risk Assessment

Gross (Macroscopic) Hematuria

  • Requires urgent urologic referral regardless of whether bleeding resolves spontaneously 1
  • Malignancy risk is 30-40%, including bladder cancer, renal cell carcinoma, and upper tract urothelial carcinoma 1
  • Never delay evaluation even if hematuria spontaneously resolves 1

Microscopic Hematuria

  • Confirm with microscopic urinalysis showing ≥3 RBCs per high-power field on two of three properly collected specimens 2
  • Malignancy risk is only 2.6-4%, allowing for systematic risk stratification 1

Essential Initial Workup

History and Physical Examination

Focus on specific malignancy risk factors:

  • Age and sex (men ≥60 years, women ≥60 years are higher risk) 1
  • Smoking history (>30 pack-years = high risk; 10-30 pack-years = intermediate risk) 1
  • Occupational exposures to aromatic amines, benzene chemicals, aristolochic acid 1
  • Blood pressure measurement at every visit 2
  • Exclude benign transient causes: vigorous exercise, menstruation, sexual intercourse, viral illness 1

Laboratory Testing

  • Microscopic urinalysis with sediment examination to assess RBC morphology and identify red cell casts 2
  • Serum creatinine to evaluate renal function 2
  • Assess for proteinuria (>300 mg/day or protein/creatinine ratio >0.3 suggests glomerular disease) 1

Distinguishing Glomerular from Non-Glomerular Sources

Glomerular Origin (Requires Nephrology Referral)

  • Dysmorphic RBCs (>80% of RBCs on phase-contrast microscopy) 1
  • Red blood cell casts 1
  • Significant proteinuria (>300 mg/day or protein/creatinine ratio >0.3) 1
  • Elevated serum creatinine 1

Non-Glomerular Origin (Requires Urologic Evaluation)

  • Normal-shaped (isomorphic) RBCs 1
  • Minimal or no proteinuria 1
  • Normal serum creatinine 1

Risk Stratification for Urologic Malignancy (Non-Glomerular Hematuria)

The American Urological Association provides specific criteria:

High-Risk Patients (1.3%-6.3% malignancy risk)

  • Men ≥60 years 1
  • 25 RBC/HPF on urinalysis 1

  • Smoking history >30 pack-years 1

Intermediate-Risk Patients (0.2%-3.1% malignancy risk)

  • Men 40-59 years or women ≥60 years 1
  • 11-25 RBC/HPF 1
  • Smoking history 10-30 pack-years 1

Low/Negligible Risk Patients (0%-0.4% malignancy risk)

  • Men <40 years and women <60 years 1
  • 3-10 RBC/HPF 1
  • Never smokers or <10 pack-years 1

Initial Imaging Strategy

For Gross Hematuria (Adults)

  • CT urography is preferred for comprehensive upper and lower tract evaluation 2
  • Renal and bladder ultrasound is an acceptable alternative if CT is contraindicated 3
  • Bladder must be adequately distended during ultrasound to avoid false-negatives 3

For Microscopic Hematuria (Risk-Based)

  • High and intermediate-risk patients: CT urography plus cystoscopy 2
  • Low-risk patients: May defer imaging initially, proceed with surveillance 2

For Pediatric Hematuria

  • Isolated microscopic hematuria without proteinuria: Imaging usually not appropriate initially 4
  • Macroscopic hematuria: Renal and bladder ultrasound is first-line to exclude tumors, stones, and anatomic abnormalities 4
  • Traumatic hematuria: CT with IV contrast if concerning mechanism, multiorgan injury, deceleration injury, flank pain/ecchymosis, or congenital renal abnormalities—even with only microscopic hematuria 4

Critical Pitfalls to Avoid

  • Never attribute hematuria solely to anticoagulation or antiplatelet therapy—these medications do not explain hematuria and require full evaluation 1
  • Do not use urine cytology or molecular markers (NMP22, BTA stat) in initial evaluation of asymptomatic microscopic hematuria 1
  • Do not delay urologic referral for gross hematuria even if bleeding resolves 1
  • Recognize that significant renal injuries can occur with microscopic hematuria in trauma—mechanism of injury matters more than degree of hematuria 1
  • In children, isolated microscopic hematuria without trauma, infection, or concerning features rarely requires imaging 1

Follow-Up Protocol for Microscopic Hematuria

After negative initial evaluation:

  • Repeat urinalysis at 6,12,24, and 36 months 2
  • Monitor blood pressure at each visit 2
  • Consider nephrology referral if hematuria persists with development of hypertension, proteinuria, or evidence of glomerular bleeding 2

References

Guideline

Differential Diagnosis of Hematuria

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Evaluation and Management of Microscopic Hematuria

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Bladder Ultrasound for Evaluating Hematuria and Anemia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.